Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 17/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823266 | 0.87 | P4HTM (0.42) | P4HTMALDH1A1MAPT | |
| SCHEMBL30871624 | 0.84 | HDAC3 (0.41) | P4HTMALDH1A1MAPT | |
| SCHEMBL6119180 | 0.84 | MAPK1 (0.53) | P4HTMKDM4EL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL18405340 | 0.81 | P4HTM (0.60) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL30112058 | 0.81 | P4HTM (0.60) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL26049197 | 0.80 | P4HTM (0.62) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL13954312 | 0.79 | P4HTM (0.61) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL19252263 | 0.79 | HPGD (0.44) | L3MBTL1TDP1 | |
| SCHEMBL27787982 | 0.78 | MAPT (0.40) | P4HTMALDH1A1MEN1MAPTNFKB1 | |
| SCHEMBL22050225 | 0.76 | P4HTM (0.58) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| EP-0667864-B1 | TRICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ZENECA LTD (GB) | 1997-09-24 | — | — | EP | disclosed |
| EP-0562734-B1 | Anti-tumour compounds containing quinazoline and tetrazole rings | ZENECA LTD (GB) | 1995-12-20 | — | — | EP | disclosed |
| EP-0373891-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-11-02 | — | — | EP | disclosed |
| EP-0562734-A1 | Anti-tumour compounds containing quinazoline and tetrazole rings | ZENECA LIMITED (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | P4HTM 2354/4885KDM4E 2865/4885L3MBTL1 4338/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P4HTM 1696/4885KDM4E 263/4885L3MBTL1 3903/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | P4HTM 2919/4885KDM4E 3393/4885L3MBTL1 4617/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P4HTM 1406/4885KDM4E 1889/4885L3MBTL1 4499/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | P4HTM 2919/4885KDM4E 3393/4885L3MBTL1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.